Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
Li Wang, Markus H. Kainulainen, Nannan Jiang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
Ruth Link‐Gelles, Matthew E. Levy, Karthik Natarajan, et al.
JAMA Network Open (2023) Vol. 6, Iss. 3, pp. e232598-e232598
Open Access | Times Cited: 65
Hydrogel armed with Bmp2 mRNA-enriched exosomes enhances bone regeneration
Zhujun Yang, Xuejian Li, Xueqi Gan, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 33
Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice
Jinge Zhou, Tianxi Ye, Yun Yang, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1779-1789
Closed Access | Times Cited: 11
Blood Markers Show Neural Consequences of LongCOVID-19
Norina Tang, Tatsuo Kido, Jian Shi, et al.
Cells (2024) Vol. 13, Iss. 6, pp. 478-478
Open Access | Times Cited: 8
Blood Biomarkers Show Neural Consequences of LongCOVID-19
Norina Tang, Tatsuo Kido, Jian Shi, et al.
(2024)
Open Access | Times Cited: 7
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Ganggang Miao, Zhiqiang Chen, Hengsong Cao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114208-114208
Open Access | Times Cited: 17
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
Hongjie Xia, Jason Yeung, Birte Kalveram, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 16
Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations
Théophile Cocherie, Karen Zafilaza, Valentin Leducq, et al.
Microorganisms (2022) Vol. 11, Iss. 1, pp. 30-30
Open Access | Times Cited: 22
Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies
Guo Du, Huaichuan Duan, Yan Cheng, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 18
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Allison Avrich Ciesla, Ryan E. Wiegand, Zachary Smith, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 10
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Traci L. Bricker, Astha Joshi, Nadia Soudani, et al.
Journal of Virology (2024) Vol. 98, Iss. 3
Open Access | Times Cited: 3
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Ziyi Chen, Zhiliang Liu, Yali Feng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves
Han Di, Elizabeth A. Pusch, Joyce Jones, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 505-505
Open Access | Times Cited: 3
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Joaquín Martínez‐López, Javier de la Cruz, Rodrigo Gil-Manso, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 379-379
Open Access | Times Cited: 2
Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants
Lei He, Qian Wu, Zhaoyong Zhang, et al.
Molecular Pharmaceutics (2024)
Closed Access | Times Cited: 2
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Tamarand L. Darling, Baoling Ying, Bradley Whitener, et al.
Med (2022) Vol. 3, Iss. 5, pp. 309-324.e6
Open Access | Times Cited: 12
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Leo Heyndríckx, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants
Nannan Jiang, Li Wang, Masato Hatta, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods
Ruth Link‐Gelles, Matthew E. Levy, Karthik Natarajan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
Catherine Jacob-Dolan, Michelle A. Lifton, Olivia Powers, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109716-109716
Open Access | Times Cited: 1
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
Sebastián Mondaca, Benjamín Walbaum, Nicole Le Corre, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1193-1193
Open Access | Times Cited: 4
Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
Hiroki Hayashi, Jiao Sun, Yuka Yanagida, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan
Yuli Wang, Shu-Tsai Cheng, Ching‐Fen Shen, et al.
Clinical and Experimental Vaccine Research (2023) Vol. 12, Iss. 4, pp. 337-337
Open Access | Times Cited: 4
SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Joshua A. Wiener, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top